Management of asthma exacerbation in adults : guidelines for primary care doctors by unknown
POLISH ARCHIVES OF INTERNAL MEDICINE 2019; 129 (11)842
Target audience of the guidelines The document 
is intended primarily for general practitioners 
(primary care physicians), general practice reg-
istrars, and general internal medicine registrars. 
However, the information provided in the guide-
lines may also be useful to healthcare managers 
and representatives of healthcare financing in-
stitutions and institutions responsible for the 
healthcare system structure.
Implementation considerations The current guide-
lines should not be seen as a legal standard of care 
for all patients. Instead, it provides some gener-
al management principles, which can aid clinical 
decision-making. Appropriate patient care op-
tions are always determined based on clinical sit-
uation and availability of treatments. All clinical 
decisions should always be consulted with the pa-
tient or their carer (if the patient lacks capacity).
Strength of recommendations The GINA Science 
Committee decided not to specify the strength 
of recommendations in their report, grading 
the quality of evidence supporting each recom-
mendation instead. Similarly, the current guide-
lines provide the quality of evidence grade (see 
TABLE 1) supporting each recommendation only if 
the original document provided such informa-
tion.3 Otherwise, the Polish adaptation does not 
provide the quality of evidence grade.
Introduction Asthma affects about 5% of the 
Polish adult population and despite modern 
treatments, exacerbations still affect a signifi-
cant percentage of patients. In order to improve 
treatment efficacy of asthma exacerbations in 
Poland, we decided to adapt the established in-
ternational guidelines on the management of 
asthma exacerbations to match the reality of 
the Polish healthcare system. The adaptation 
process was guided by the ADAPTE Collabora-
tion toolkit.1 The key stages included: deter-
mining health questions, searching for guide-
lines and other relevant documents followed by 
assessment of their quality, selecting the best 
guidelines and recommendations to create an 
adapted guideline.1,2 Global Initiative for Asth-
ma (GINA) Guidelines (www.ginasthma.org) 
were selected as the source document and rel-
evant recommendations concerning asthma ex-
acerbations were adopted and customized to 
match local conditions in Poland.3 This docu-
ment was endorsed by the Country Consultant 
in Family Medicine and College of Family Phy-
sicians in Poland. The current guidelines apply 
to adults with asthma.
The aim of the guidelines on the management 
of asthma exacerbations in adults is to improve 
the safety of patients by ensuring appropriate 
prevention of exacerbations and appropriate 
treatment.
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* KJ is a representative of patients 
with asthma.
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10 Pregnancy 
11 Ever intubated or in intensive care unit for 
asthma
12 One or more severe exacerbation in last 
12 months
Items 1 to 9 are considered modifiable risk 
factors.
Clinical presentation: diagnosing exacerbations 
Asthma exacerbation manifests as an increased 
severity of dyspnea, cough, wheeze, and chest 
tightness that exceeds usual day-to-day variabil-
ity.10 The symptoms are usually accompanied by 
a decline in lung function (decreased PEF or FEV1) 
compared with the patient’s previous lung func-
tion or predicted values (or maximum values for 
that patient). Lung function measurements en-
able objective assessment of exacerbation severi-
ty. Some patients (more often men or those with 
near-fatal asthma) may perceive symptoms poor-
ly. The asthma control test is not a reliable tool to 
make a diagnosis of exacerbation.
Exacerbations usually occur in response to: 
exposure to an external agent (eg, viral upper 
respiratory tract infection, pollen, or pollution) 
and / or poor adherence with controller medica-
tion.11 Some patients present more acutely and 
without exposure to known risk factors. Severe 
exacerbation can occur in patients with mild or 
well-controlled asthma.
History and physical examination The history tak-
en from a patient with asthma exacerbation (or 
their next of kin in patients with severe exacer-
bation) should ascertain the following:
•	  Duration of exacerbation
•	  Potential causes if known (eg, allergen expo-
sure or viral respiratory tract infection)
•	  Severity of asthma symptoms
•	  Presence and severity of other symptoms, in 
particular anaphylaxis
Definition and epidemiology of asthma exacerbations 
Exacerbations of asthma are episodes character-
ized by worsening in symptoms (dyspnea, cough, 
wheeze, and chest tightness), which represent 
a change from the patient’s usual status that is 
sufficient to require a change in treatment. The 
status asthmaticus (acute severe asthma, J46 ac-
cording to the International Classification of Dis-
eases, Tenth Revision) is defined as an episode of 
severe, life-threatening exacerbation of asthma.
The epidemiologic data is limited. In 2010, 
an estimated 8.2% of adults from the United 
States had current asthma, and approximate-
ly 50% of those had had an asthma attack in 
the past year.4
Risk factors for asthma exacerbations The key as-
pect in preventing asthma exacerbations is the 
awareness of risk factors, which include5-9:
1 Uncontrolled asthma symptoms (the key risk 
factor) 
2 High use of short-acting β2-agonist (SABA), 
which indicates uncontrolled asthma symptoms; 
mortality increased if one 200-dose canister is 
used per month
3 Inadequate use of inhaled corticosteroids 
(ICSs), nonadherence, poor inhaler technique
4 Low forced expiratory volume in 1 second 
(FEV1), especially if less than 60% predicted
5 Excessive (>10%) variability of peak expi-
ratory flow (PEF); daily diurnal PEF variabili-
ty should be calculated using the following for-
mula: [PEFmax – PEFmin] / PEFmean; and av-
eraged over 1 week.
6 Major psychological or socioeconomic problems
7 Exposures: smoking, allergen exposure if sen-
sitized 
8 Comorbidities: obesity, rhinosinusitis, con-
firmed food allergy 
9 Sputum or blood eosinophilia, elevated frac-
tional exhaled nitric oxide (in adults on long-
term ICS) 
TABLE 1 Description of evidence (quality) levels used in the reports of the Global Initiative for Asthma
Evidence 
level
Source(s) of evidence Definition
A RCTs and meta-analyses; 
rich body of data
Evidence is from endpoints of well-designed RCTs or meta-analyses that 
provide a consistent pattern of findings in the population for which the 
recommendation is made. Category A requires substantial numbers of 
studies involving substantial numbers of participants.
B RCTs and meta-analyses; 
limited body of data
Evidence is from endpoints of intervention studies that include only 
a limited number of patients, post-hoc or subgroup analysis of RCTs or 
meta-analysis of such RCTs. Category B pertains when few randomized 
trials exist, they are small in size, they were undertaken in a population 
that differs from the target population of the recommendation, or the 
results are somewhat inconsistent.
C Nonrandomized trials; 
observational studies
Evidence is from endpoints of uncontrolled or nonrandomized trials, or from 
observational studies.
D Panel consensus 
judgement
This category is used only in cases where the provision of some guidance 
was deemed valuable but the clinical literature addressing the subject 
was insufficient to justify placement in one of the other categories. The 
panel consensus is based on clinical experience or knowledge that does 
not meet the above criteria.
Abbreviations: RCT, randomized clinical trial
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Peak expiratory flow measurement or spirometry 
Lung function tests (PEF and spirometry) are 
intended for the assessment of exacerbation se-
verity and treatment efficacy.14 They facilitate 
the decision to send patient home (eg, with PEF 
>60%–80% of predicted or personal best). In pa-
tients with asthma exacerbation, current PEF or 
FEV1 values should be compared with previous 
measurements (if available) and with predicted 
or personal best values.
Lung function tests enable more objective, re-
liable assessment of exacerbation severity than 
clinical presentation.
Comment: Lung function tests should not be 
performed in patients who present with signs of 
severe exacerbation (see TABLE 3). PEF measure-
ment can be preferred as easier and less demand-
ing of a patient, except for the mildest cases, in 
which accurate lung function assessment may af-
fect subsequent management.
Pulse oximetry Pulse oximetry facilitates as-
sessing exacerbation severity.15 Saturation lev-
els (SpO2) of less than 90% signal the need for ag-
gressive therapy. Pulse oximetry is useful for ti-
trating oxygen therapy (target SpO2 is 93%–95%) 
as well as for reviewing the response and the pos-
sibility to send the patient home (whereby SpO2 
of >94% when on air is required).
Assessing the severity of exacerbation  Assess-
ment of exacerbation severity should be based 
•	  Risk factors for exacerbations and asthma-re-
lated death (see TABLE 2)
•	  All current medications, including doses and 
devices prescribed, adherence pattern, any re-
cent dose changes and response to current 
therapy
The physical examination of a patient with 
asthma exacerbation should assess12,13:
•	  Vital signs: level of consciousness, tempera-
ture, heart rate, respiratory rate, blood pressure
•	  Signs of bronchoconstriction (prolonged expi-
ration, wheezing, rhonchi) and other abnormal 
findings of chest assessment (suggesting alter-
native conditions which may explain worsened 
patient’s status, eg, pneumonia, pneumothorax, 
or heart failure)
•	  Additional findings, which facilitate objective 
assessment of exacerbation severity, such as abil-
ity to complete sentences or utter words, which 
may be impaired due to dyspnea, and use of ac-
cessory muscles
•	  Nonrespiratory signs suggesting alternative 
explanations of acute breathlessness (eg, stridor, 
rash, lower extremity edema)
The sensitivity of assessment based only on his-
tory and physical examination is limited, as symp-
tom severity may not always accurately reflect the 
degree of bronchoconstriction in some patients.
Additional investigations  The following tests 
should be performed in a patient with asthma 
exacerbation in a primary care setting.
TABLE 2 Factors that increase the risk of exacerbations and asthma-related death
•  History of asthma exacerbation requiring intubation and mechanical ventilation
•  Hospitalization or emergency care (emergency department) visit for asthma exacerbation in the past year
•  Current or recent use of oral CS
•  Not currently using ICS
•  Overuse of SABA (using >1 × 200-dose canister / mo is a red flag)
•  History of psychiatric disease and / or psychosocial problems
•  Poor adherence to asthma medications or poor adherence to (or lack of) a written asthma action plan
•  Symptoms of food allergy
Abbreviations: CS, corticosteroid; ICS, inhaled corticosteroid; SABA, short-acting β2-agonist
TABLE 3 Asthma exacerbation severity assessment criteria according to the Global Initiative for Asthma 20183
Parameter Exacerbation severity
Mild / moderate Severe Life-threatening
Dyspnea / body position Sits upright Sits hunched forwards Sits hunched forwards
Speech Talks in phrases Talks in words Talks in words
Level of consciousness Normal Agitated Drowsy, confused
Respiratory rate Increased but ≤30 breaths/min >30 breaths/min >30 breaths/min
Accessory muscles in use No Yes Paradoxical breathing
Heart rate 100–120 bpm >120 bpm >120 bpm or 
bradycardia
PEF, % predicted >50% ≤50% optionally
SpO2 (on air) 90%–95% <90% <90%
Abbreviations: PEF, peak expiratory flow; SpO2, peripheral capillary oxygen saturation
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or personal best), long-lasting (3–4 hours) re-
sponse to initial treatment.
Dosage with pMDI with a spacer should be 4 to 
10 puffs repeated every 20 minutes for 1 hour. Af-
ter the first hour, depending on the response, the 
dose of SABA required varies from 4 to 10 puffs 
every 3 to 4 hours up to 6 to 10 puffs every 1 to 
2 hours (or more often if needed). No addition-
al SABA is needed if there is a good response to 
initial treatment (eg, PEF >60%–80% of predict-
ed or personal best for 3–4 hours).
Dosage with nebulizer should be 2.5 to 5 mg 
of salbutamol, with the dose depending on the 
severity of exacerbation. A single dose of 2.5 to 
5 mg administered over 30 minutes is usually suf-
ficient. If needed, it can be repeated up to 4 times 
a day. Higher doses, up to 40 mg, can only be used 
in an inpatient setting.
Drugs available in Poland are: fenoterol (pMDI 
100 µg per puff), salbutamol (pMDI and DPI 100 
µg per puff and 200 µg per puff, nebulizer solu-
tion 2.5 g/2.5 ml and 5 mg/2.5 ml, respectively).
Oxygen therapy Oxygen therapy should be used, 
if available, and titrated to maintain SpO2 at 93% 
to 95%.20,21 Such modality gives better clinical 
outcomes and is safer than high-flow 100% ox-
ygen therapy (level of evidence, B). The unavail-
ability of pulse oximeter is not a contraindication 
for oxygen therapy.
Oral corticosteroids Oral corticosteroids (OCSs) 
should be used in all patients, except for those 
with mildest exacerbations, especially if they fail 
to respond to an increase in reliever and control-
ler medications after 2 to 3 days, deteriorate rap-
idly, have PEF or FEV1 of less than 60% of their 
personal best or predicted value, or have a histo-
ry of sudden severe exacerbations.
Prompt administration of systemic corticoste-
roids (oral or intravenous) improves clinical out-
comes in patients with asthma exacerbation.22 
Systemic corticosteroids should be administered 
within 1 hour of presentation,23 followed by a 5- 
to 7-day course with once a day (a.m.) adminis-
tration (level of evidence, B). Oral administra-
tion is as effective as intravenous. Systemic cor-
ticosteroids enhance resolution of exacerbations 
and prevent relapse.
Dosage of prednisolone should be 1 mg/kg/d 
(maximum dose is 50 mg/d) or an equivalent dose 
of another OCS.
Drugs that are available in Poland are as fol-
lows: prednisone (tablets 1, 5, 10, and 20 mg), 
prednisolone (tablets 5 mg), methyloprednis-
olone (tablets 4, 8, and 16 mg), triamcinolone 
(tablets 4 mg).
Management of severe asthma exacerbation Patients 
presenting with life-threatening asthma exacer-
bation / impaired consciousness should be trans-
ferred to the emergency department by the Ad-
vanced Life Support ambulance (the “S” catego-
ry ambulance in Poland). In the remaining cases, 
on the degree of dyspnea, respiratory rate, heart 
rate, SpO2, and PEF (or FEV1). See TABLE 3.
Criteria for hospitalization The decision about hos-
pitalization should be based on:
•	  Clinical status
•	  Lung function
•	  Response to treatment
•	  Recent and past history of exacerbations
•	  Ability to manage at home
Patients with severe or life-threatening exacer-
bation should be immediately transferred to the 
hospital. Whilst awaiting the transfer, the treat-
ment outlined below should be initiated.
Comment: The decision to admit or discharge 
should be based on the clinical status (including 
the ability to lie flat) and lung function 1 hour af-
ter commencement of treatment rather than the 
patient’s status on arrival.
The risk factors mentioned below should be 
considered to inform the decision to admit or 
discharge16:
•	  Female sex, older age, and nonwhite race
•	  Use of more than eight SABA puffs in the pre-
vious 24 hours
•	  Cardiopulmonary resuscitation or other emer-
gency medical intervention at the emergency 
department
•	  Severe exacerbation (respiratory rate >30 
breaths/min, oxygen saturation <90%, final PEF 
<50% predicted)
•	  Past history of severe exacerbations (eg, 
intubation)
•	  Previous unscheduled office and emergency 
department visits requiring use of oral CS.
Patients who are at risk of severe exacerbation 
and asthma-related death require prompt medical 
intervention and close monitoring (see TABLE 2).
Management of asthma exacerbation Management 
of mild / moderate asthma exacerbation Patients 
with mild / moderate asthma exacerbation can be 
managed by a general practitioner in a primary 
care setting. They should remain in the primary 
care facility for at least 1 hour after initial treat-
ment. If there is an improvement in vital signs 
and PEF (>60%–80% of predicted or personal 
best), the patient does not need SABA, and has 
SpO2 >94% when on air, they can be sent home 
after arranging follow-up visits.
Comment: Maintenance controller treatment 
with ICS at the dose 2- to 4-fold higher than the 
usual dose should be continued for 10 to 14 days.17 
With OCS, the maintenance treatment should be 
continued for 5 to 7 days.
Short-acting β2-agonist Treatment of asthma ex-
acerbation should start with SABA. It can be 
delivered by a pressurized metered-dose in-
haler (pMDI) with a spacer or by a nebuliz-
er.18,19 The efficacy of both is comparable in 
patients with mild / moderate exacerbation 
(level of evidence, A). No additional SABA is need-
ed if there is a good (PEF >60%–80% of predicted 
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should not be routinely used in the management 
of asthma exacerbation include:
•	  Theophylline (due to low efficacy and high risk 
of adverse effects)25
•	  Antibiotics (unless there is a bacterial lower 
respiratory tract infection or pneumonia)
•	  Sedatives (contraindicated in asthma 
exacerbation)
•	  Adrenaline (except for patients whose bron-
choconstriction is secondary to anaphylaxis)
Assessing treatment response in patients with asthma 
exacerbation The following should be monitored 
in patients with asthma exacerbation as a part 
of treatment response assessment: level of con-
sciousness, respiratory rate, heart rate, SpO2, se-
verity of dyspnea and other signs of exacerbation.
The patients should be periodically followed-
up for the presence and severity of signs of ex-
acerbation and changes in lung function (PEF 
measurement 1 hour after treatment commence-
ment or earlier).
Patients with little or slow response to SABA 
treatment should be closely monitored.
Additional treatment should continue until 
PEF reaches a plateau or (ideally) returns to the 
patient’s previous best.
Patients who fail to respond to treatment or 
who continue to deteriorate should be transferred 
immediately to an acute care facility.
Follow-up after asthma exacerbation In patients in 
whom a good control of exacerbation was achieved 
in a primary-care setting, a follow-up appoint-
ment should be arranged about 2 to 7 days later 
(level of evidence, D).
Once symptom control has been achieved, ad-
herence should be assessed, and maintenance 
treatment planned.26 Maintenance treatment 
should include initiation or stepping up the con-
troller for 2 to 4 weeks or 2 to 3 months, de-
pending on the cause of exacerbation). Most 
patients not currently taking controller medi-
cation should usually be commenced on regular 
ICS-containing therapy, as an exacerbation re-
quiring medical care indicates that the patient 
is at increased risk of future exacerbations (lev-
el of evidence, B).
Individualized asthma action plan All patients 
should be provided with a written, individualized 
asthma action plan that includes current thera-
pies and is appropriate for the patient’s education 
and understanding.27 The asthma action plan en-
ables the patient to self-manage and respond ap-
propriately to worsening symptoms of exacerba-
tion and / or changes in PEF, providing guidance 
as to changes in reliever and controller medica-
tions, how to use OCSs, and when and how to ac-
cess medical care (general practice / ambulance).28
After a self-managed exacerbation, patients 
should see their primary care healthcare provid-
er within 1 to 2 weeks to assess symptom control 
and additional risk factors for exacerbations, and 
the Basic Life Support ambulance (the “P” catego-
ry ambulance in Poland) is appropriate.
Short-acting bronchodilator Short-activng bronchodi-
lators are best administered via an oxygen-powered 
nebulizer. If a nebulizer is not available, a pMDI 
with a spacer is the preferred delivery method.
Dosage of SABA should be 2.5 to 5 mg of salbu-
tamol via a nebulizer (consider continuous nebuli-
zation at 10 mg/h or up to 10 doses administered 
every 20 minutes via a pMDI + spacer).
Dosage of short-acting muscarinic antagonist 
should be 0.5 to 0.75 mg of ipratropium bromide 
via a nebulizer or up to 10 doses administered via 
a pMDI with a spacer.
Ipratropium (pMDI 20 µg per puff, nebuliz-
er solution 0.25 mg/ml) is available in Poland.
Oxygen therapy Oxygen therapy should be titrat-
ed to maintain SpO2 at 93% to 95%.
21
Systemic corticosteroids Systemic corticoste-
roids, oral or intravenous (comparable effica-
cy), should be administered within the first 
hour of treatment, dosage as in mild / moder-
ate exacerbation.23
Management of exacerbations in patients with asthma–
chronic obstructive pulmonary disease overlap The 
treatment should be in line with the guidance for 
the management of asthma and chronic obstruc-
tive pulmonary disease, including systemic corti-
costeroids administered shortly after presentation, 
stepped up inhaled bronchodilators (both SABA 
and short-acting muscarinic antagonist should be 
used; dosage, as above), controlled oxygen thera-
py, and antibiotics (if indicated).
Adverse effects of drugs used for the management of 
asthma exacerbations Although drugs used for 
the management of asthma hardly give system-
ic adverse effects, the risk of adverse effects in-
creases with higher doses of medications admin-
istered to patients with exacerbations.
Comment: Hypoxemia, which may occur in pa-
tients with asthma exacerbation, may increase the 
risk of adverse effects of β2-agonists. The most 
common adverse effects of β2-agonists include: 
tachycardia and less often other arrhythmias (ec-
topic beats, atrial fibrillation); skeletal muscle 
tremor; hypokalemia; hyperglycemia.
Their presence and severity depend on the dose 
of a medication and the degree of hypoxemia. 
Therefore, high doses of β2-agonists necessary 
to produce optimum bronchodilation should be 
used alongside oxygen therapy and corticoste-
roids, which can reduce the risk of adverse effects. 
The need to administer corticosteroids is likely to 
be overlooked due to the short-term bronchodi-
lation effect of β2-agonists, which may mask the 
severity of exacerbation.
Medications not to be routinely used in the manage-
ment of asthma exacerbation Medications that 
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In patients with an acute deterioration, high-
dose ICS for 7 to 14 days (500–1600 μg beclo-
metasone dipropionate equivalent) is as effective 
as a short course of OCS (level of evidence, A).
Combination inhaled corticosteroids with long-acting 
β2-agonist The combination of rapid-onset long-
acting β2-agonist (formoterol) and low-dose ICS 
(budesonide or beclomethasone) in a single inhal-
er as both the controller and the reliever medica-
tion is effective in improving asthma control and 
reduces exacerbations requiring OCS and hospi-
talizations. The maximum total formoterol dose 
is 72 µg/d.30
The ICS dose may be further increased by add-
ing a separate ICS inhaler.
Patient education Patients after exacerbations 
are more likely to implement behavioral chang-
es. They should be referred to an asthma educa-
tion program, if one is available.31 It is particu-
larly true for patients discharged following an 
emergency department presentation or hospi-
talization for asthma. Patients who were hospi-
talized may be particularly receptive to informa-
tion and advice about their illness.
An educational program should contain in 
particular:
•	  Training aiming at effective use of inhaler de-
vices (up to 70%–80% of patients are unable to 
use their inhaler correctly—poor inhaler tech-
nique leads to poor asthma control)
•	  Encouraging adherence (up to 50% of patients 
fail to take medications as directed at least part 
of the time)
to identify the potential cause of the exacerba-
tion. Patients should contact their doctor if they 
start taking OCS.
During the follow-up appointment after a self-
managed exacerbation, the written asthma ac-
tion plan should be reviewed to see whether an 
update is needed.
Possible options for treatment modification as 
a part of self-management of asthma exacerba-
tions are presented in TABLE 4.
Treatment modifications as part of self-management 
of exacerbations Short-acting β2-agonist Repeat-
ed dosing with inhaled SABA bronchodilators pro-
vides temporary relief until the cause of the symp-
tom worsening passes or treatment with an in-
creased-dose controller has had time to take effect. 
SABA should be delivered via pMDI with a spac-
er or via a nebulizer. The need for repeated doses 
over more than 1 to 2 days signals the need to re-
view, and possibly increase, controller treatment.
Rapid-onset long-acting β2-agonists (formoterol) The 
use of the rapid-onset long-acting β2-agonist, for-
moterol, in a separate inhaler is not recommend-
ed in order to avoid the possibility of it being used 
without the concomitant ICS.
Inhaled corticosteroids At least doubling the ICS 
dose as a part of asthma action plan–based self-
management of exacerbation improves asthma out-
comes and reduces healthcare utilization. Quadru-
pling the ICS dose (to an average of 2000 μg/d be-
clometasone dipropionate equivalent) in response 
to a decrease in PEF limits the need for OCS.29
TABLE 4 Treatment modifications in adults with worsening asthma to be used in a written asthma action plan
Medications Short-term change (1–2 weeks) for worsening asthma Level of 
evidence
Increase usual reliever
SABA For pMDI, add spacer A
Low-dose ICS / formoterol Increase formoterol as needed up to the maximum of 
72 µg/d
A
Usual controller, step-up treatment
Maintenance and reliever 
ICS / formoterol
Continue maintenance ICS / formoterol and increase 
ICS / formoterol reliever (maximum formoterol total 72 µg/d)
A
Maintenance ICS + SABA as reliever At least double ICS, consider increasing ICS to high dose (to 
maximum total of 2000 µg/d BDP equivalent)
B
Maintenance ICS / formoterol + 
SABA as reliever
Quadruple maintenance ICS / formoterol (maximum 
formoterol 72 µg/d)
B
Maintenance ICS / other LABA + 
SABA as reliever
Step up to higher dose formulation of ICS / other LABA or 
consider adding a separate ICS inhaler (to maximum total 
of 2000 µg/d BDP equivalent)
D
OCS (prednisone or prednisolone) Add OCS in severe exacerbations (PEF or FEV1 <60% 
personal best or predicted) or patient not responding to 
treatment over 48 hours
A
Prednisolone 1 mg/kg/d (maximum 50 mg), usually for 5–7 d D
Tapering is not needed if a short-term (<2 weeks) OCS 
course is prescribed
B
Abbreviations: BDP, beclometasone dipropionate; FEV1, forced expiratory volume in 1 second; LABA, long-acting 
β2-agonist; OCS, oral corticosteroid; PEF, peak expiratory flow; pMDI, pressurized metered-dose inhaler; others, 
see TABLE 2
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qualifications of physicians through nationwide, standardized training in di-
agnostic management, treatment and prevention of diseases” (in Polish: 
Podnoszenie kwalifikacji lekarzy poprzez przeprowadzenie ogólnopolskich 
standaryzowanych szkoleń w zakresie postępowania diagnostycznego, ter-
apii oraz profilaktyki), cofinanced from the European Union funds: the Euro-
pean Social Fund, priority axis 5—“Support for healthcare,” activity 5.4 “De-
veloping professional competences and qualifications of medical staff,” the 
Operational Programme Knowledge Education Development. The financing 
institution has not influenced the content of the current guidelines.
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It should also include information regarding:
•	  Asthma
•	  The causes of asthma exacerbations and the 
ways to prevent them
•	  The actions the patient needs to take to re-
spond to symptom worsening or a subsequent 
exacerbation
The strategies to reduce the risk of exacerba-
tions are shown in TABLE 5.
Review and update plan The current document 
will be reviewed and updated as new important re-
search data and the updated version of the GINA 
global strategy containing significant changes to 
the recommendations regarding management of 
asthma exacerbations become available.
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TABLE 5 Treating modifiable risk factors to reduce exacerbations
Patient group / risk factor Treatment strategy Level of 
evidencea
Any patient with ≥1 risk factor 
for exacerbations (including 
poor symptom control)
Regular use of ICS A
A written action plan for the management of asthma A
More frequent reviews A
Regular control of inhaler technique A
Identification of modifiable risk factors D
≥1 severe exacerbation in last 
year
Consider alternative controller regimens to reduce exacerbation 
risk, eg, ICS / formoterol maintenance and reliever regimen
A
Consider stepping up treatment if no modifiable risk factors A
Identify any avoidable triggers for exacerbations C
Exposure to tobacco smoke Encourage smoking cessation A
Consider higher dose of ICS if asthma poorly-controlled B
Low FEV1, especially if <60% 
predicted
Consider trial of 3-month treatment with high-dose ICS or 2-week 
treatment with OCS
B
Exclude other lung disease, eg, COPD D
Refer for expert advice if no improvement D
Obesity Suggest weight loss B
Distinguish asthma symptoms from symptoms due to restrictive 
lung diseases and / or obstructive sleep apnea
D
Major psychological problems Consider mental health assessment D
Help patient to distinguish between symptoms of anxiety and 
asthma; educate the patient how to manage panic attacks
D
Major socioeconomic problems Offer less expensive medications D
Confirmed food allergy Advise appropriate food avoidance and remind the patient to have 
injectable epinephrine on them at all timesb
A
Allergen exposure if sensitized Consider possibility of reducing allergen exposure (consider cost) C
Consider stepping up of controller treatment D
Consider adding allergy immunotherapy, which is effective, but is 
associated with a risk of serious systemic adverse effects when 
administered subcutaneously
A
Sputum eosinophilia Increase ICS dose independent of level of symptom control A
a Level of evidence in the table applies to the efficacy of a given treatment in the management of asthma (assessed 
by means of different endpoints) rather than risk reduction in patients after exacerbations.
b Comment: The patient and their next of kin should be provided with detailed, preferably written, instructions for 
how and when to use the prescribed medications.
Abbreviations: COPD, chronic obstructive pulmonary disease; others, see TABLES 2 and 4
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